Immunosuppressants - Philippines | Statista Market Forecast

The Immunosuppressants market in the Philippines is expected to achieve a revenue of US$53.49m by 2024.
Furthermore, it is projected to experience an annual growth rate (CAGR 2024-2029) of 16.31%, leading to a market volume of US$113.90m by 2029.
When compared globally, United States is anticipated to generate the highest revenue in this market, amounting to US$35.47bn in 2024.
The demand for immunosuppressants in the Philippines is steadily rising due to an increasing number of organ transplant surgeries in the country.

Definition:
The Immunosuppressants market covers drugs which suppress the immune response. These remedies are used in different therapy areas, mainly to treat auto-immune diseases, such as psoriasis. Anti-rejection drugs administered after organ transplantations are also included in this market. Monoclonal antibodies are an important type of immunosuppressant.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Johnson & Johnson, Sanofi, Novartis

Drugs to suppress the immune response
Immunosuppressants to treat auto-immune diseases, such as psoriasis
Anti-rejection drugs

Multiple sclerosis drugs
Anti-rheumatic drugs
Immuno-oncology drugs
Antivirals
Antibiotics
Corticosteroids
HIV drugs

The demand for Immunosuppressants in the Philippines has been on the rise in recent years.

Customer preferences: The increase in demand for Immunosuppressants in the Philippines can be attributed to the growing number of patients with autoimmune diseases, such as lupus and rheumatoid arthritis. These patients require medication to suppress their immune system and prevent it from attacking their own body.

Trends in the market: The Immunosuppressants market in the Philippines is expected to continue to grow in the coming years due to the increasing prevalence of autoimmune diseases in the country. Additionally, the availability of generic Immunosuppressants is also contributing to the growth of the market as it makes the medication more affordable for patients.

Local special circumstances: One unique aspect of the Immunosuppressants market in the Philippines is the high cost of branded medications. This has led to a preference for generic medications among patients, which has further fueled the growth of the market.

Underlying macroeconomic factors: The Philippines has a growing economy and an expanding healthcare sector, which is contributing to the growth of the Immunosuppressants market. Additionally, the government has implemented policies to improve access to healthcare for all Filipinos, which has led to an increase in the number of patients seeking treatment for autoimmune diseases.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.